The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive organisms in adults.
Giammarco Baiardi +8 more
doaj +1 more source
Acute drug effects on habitual and non-habitual responding in crossed high alcohol preferring mice [PDF]
RATIONALE: Drug reward plays a central role in acquiring drug-seeking behavior. However, subjects may continue using drugs despite negative consequences because self-administration becomes habitual, and divorced from outcome values. Although a history
Grahame, Nicholas J., Houck, Christa A.
core +1 more source
Individual and county-level factors associated with use of multiple prescribers and multiple pharmacies to obtain opioid prescriptions in California. [PDF]
Use of multiple prescribers and pharmacies is a means by which some individuals misuse opioids. Community characteristics may be important determinants of the likelihood of this phenomenon independent of individual-level factors. This was a retrospective
Han, Huijun +3 more
core +5 more sources
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. [PDF]
Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients with acute myeloid leukemia (AML). The optimal treatment schedule and optimal timing of GO administration relative to other agents remains ...
Eva Jager +5 more
doaj +1 more source
Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides [PDF]
Objective: Patients included in MAINRITSAN2 trial received either an individually tailored or a fixed-schedule therapy with rituximab as maintenance treatment of antineutrophil cytoplasm antibody associated vasculitides.
Ana Belén Guisado-Gil +4 more
doaj +1 more source
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model [PDF]
Gemcitabine shows a marked antitumor effect as a result of its cytotoxic action toward proliferative cells. In this article, we aim to investigate the potential antitumor and antiangiogenic effect of gemcitabine following a metronomic schedule that ...
Capellá, G. (Gabriel) +9 more
core +1 more source
Sequential dose-dense single agent chemotherapy for locally advanced breast cancer [PDF]
Chemotherapy of breast cancer is still the area of intensive research. Based on mathematical model of tumor cell growth kinetics, articulated by Larry Norton, novel concept of chemotherapy in breast cancer was launched and it implies dose-densification ...
Vrbić Svetislav +3 more
doaj +1 more source
Resumen: Introducción: La otitis media aguda (OMA) es una de las causas más frecuentes de consulta y prescripción antibiótica en pediatría. El objetivo de este trabajo es valorar la prescripción antibiótica diferida en OMA en pediatría en atención ...
María García Ventura +2 more
doaj +1 more source
Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter [PDF]
Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
Babich, John W +7 more
core +1 more source
Failure of Intravenous Morphine to Serve as an Effective Instrumental Reinforcer in Dopamine D2 Receptor Knock-Out Mice [PDF]
The rewarding effects of opiates are thought to be mediated through dopaminergic mechanisms in the ventral tegmental area, dopamine-independent mechanisms in the nucleus accumbens, or both. The purpose of the present study was to explore the contribution
Elmer, Greg I. +5 more
core +1 more source

